BioNexus Gene Lab
BGLC
5 hedge funds and large institutions have $55.9K invested in BioNexus Gene Lab in 2023 Q4 according to their latest regulatory filings, with 1 funds opening new positions, increasing their positions, 3 reducing their positions, and 1 closing their positions.
0% more funds holding
Funds holding: 5 → 5 (0)
0% more first-time investments, than exits
New positions opened: 1 | Existing positions closed: 1
0.06% less ownership
Funds ownership: 0.12% → 0.06% (-0.06%)
67% less capital invested
Capital invested by funds: $171K → $55.9K (-$116K)
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 3
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TRCT
Tower Research Capital (TRC)
New York
|
+$3.31K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
HF
HRT Financial
New York
|
-$38K |
| 2 |
VF
Virtu Financial
New York
|
-$19.1K |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$10.3K |
| 4 |
TSS
Two Sigma Securities
New York
|
-$4.59K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
Citadel Advisors
Miami,
Florida
| $18.1K | -$10.3K | -1,816 | -35% |
|
|
VF
2
Virtu Financial
New York
| $14K | -$19.1K | -3,354 | -56% |
|
3
Geode Capital Management
Boston,
Massachusetts
| $12.8K | – | – | – |
|
|
TSS
4
Two Sigma Securities
New York
| $7.91K | -$4.59K | -807 | -35% |
|
|
TRCT
5
Tower Research Capital (TRC)
New York
| $3.09K | +$3.31K | +583 | New |
|
|
HF
6
HRT Financial
New York
| – | -$38K | -4,547 | Closed |
|
BGLC Hedge Fund Activity: Q4 2023 in Review
5 of the 6,860 institutional investors tracked by Wall St. Rank reported a position in BioNexus Gene Lab (BGLC) for Q4 2023, worth a combined $55.9K — down 67% from $171K a quarter earlier.
Fund positioning in BGLC was balanced in Q4 2023: 1 fund opened new positions, 1 closed out, 0 added to existing stakes and 3 trimmed.
The largest buyer was Tower Research Capital (TRC), opening a new position worth an estimated $3.31K. The largest seller was HRT Financial, exiting entirely with an estimated $38K sold.
- 5 institutional investors held BioNexus Gene Lab (BGLC) as of Q4 2023, unchanged from Q3 2023.
- Funds reported $55.9K of BioNexus Gene Lab stock for Q4 2023, down 67% quarter-over-quarter.
- 1 fund opened new BioNexus Gene Lab positions in Q4 2023 and 1 closed out, a net change of 0 holders.
- The largest BioNexus Gene Lab buyer in Q4 2023 was Tower Research Capital (TRC), an estimated $3.31K added.
- The largest BioNexus Gene Lab seller in Q4 2023 was HRT Financial, an estimated $38K sold.
Based on aggregated 13F filings for Q4 2023.